Antares Pharma, Inc. (NASDAQ:ATRS)’s share price traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $4.38 and last traded at $4.44. 2,747,716 shares changed hands during trading, an increase of 101% from the average session volume of 1,369,723 shares. The stock had previously closed at $4.78.
Several research analysts recently issued reports on the company. TheStreet upgraded Antares Pharma from a “c” rating to a “b-” rating in a research report on Wednesday, November 25th. Zacks Investment Research downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $5.15.
The stock has a market capitalization of $740.02 million, a PE ratio of 79.68 and a beta of 1.44. The company has a current ratio of 2.47, a quick ratio of 2.08 and a debt-to-equity ratio of 0.53. The company’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $3.41.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership grew its stake in shares of Antares Pharma by 10.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 485,133 shares of the specialty pharmaceutical company’s stock valued at $1,310,000 after buying an additional 45,120 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Antares Pharma during the 3rd quarter valued at $3,255,000. IndexIQ Advisors LLC grew its stake in shares of Antares Pharma by 11.5% during the 4th quarter. IndexIQ Advisors LLC now owns 88,748 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 9,163 shares during the period. Mackay Shields LLC purchased a new stake in shares of Antares Pharma during the 3rd quarter valued at $595,000. Finally, HealthInvest Partners AB purchased a new stake in shares of Antares Pharma during the 4th quarter valued at $6,863,000. 39.92% of the stock is owned by institutional investors.
About Antares Pharma (NASDAQ:ATRS)
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Further Reading: What is an economic bubble?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.